MaxCyte price target lowered to $9 from $11 at Stifel

Stifel lowered the firm’s price target on MaxCyte (MXCT) to $9 from $11 and keeps a Buy rating on the shares. Management’s guidance for 2025 positions core revenues as up 8%-15%, notes the analyst, who adds that there “does appear to be upside potential to the guide,” most notably from an embedded assumption that end markets do not improve. The firm continues to like MaxCyte as a play on what should be a rebound year for cell therapy, but “the pace at which the thesis plays out could be on the slower side,” the analyst added.